Renal Cell Carcinoma

A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.

The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.

Immune checkpoint inhibitor-based treatment was equally effective as a frontline treatment for both Black and White patients with metastatic renal cell carcinoma in separate analyses.

During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, asked participants to share their experiences using nivolumab plus cabozantinib in patients with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Provide perspective on quality-of-life observations with different IO-TKI regimens and supporting evidence.

Dr. Hammers outlines his thought process around TKI/ICI dose modifications vs discontinuations with toxicity and discusses toxicity management recommendations.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.

Dr. Motzer discusses his view on the appropriateness of the initial therapy for this nccRCC patient, including key factors he considers when deciding on initial treatment.

Dr. Motzer provides his perspective on the notable aspects of this nccRCC case and how it compares to typical cases.

Hedyeh Ebrahimi, MD, discussed a novel approach to targeting metastatic renal cell carcinoma through a microbiome-mediated pathway.

Dr. Hammers shares his experience with high-grade AEs in IO-TKI treated patients and how toxicities are mitigated/managed.

Dr. Hammers explains factors involved in decision-making between immunotherapy-based treatment options.

New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.

Dr. Hammers discusses recent efficacy and safety data updates from CHECKMATE-214, KEYNOTE-426, and CHECKMATE-9ER trials.

Dr. Hammers summarizes key efficacy findings from the CLEAR study of pembrolizumab + lenvatinib vs sunitinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.

Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.

Dr. Hammers discusses initial impressions of the case presentation, comparing it to typical advanced RCC, and reviewing risk factors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on what role risk stratification plays in selecting frontline therapy for a patient with metastatic renal cell carcinoma. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, and participants explored the third-line treatment options for a patient with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.

Subcutaneous nivolumab coformulated with rHuPH20 showed noninferiority of PK exposures compared with intravenous nivolumab in metastatic ccRCC.

Adjuvant pembrolizumab treatment significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a heightened risk of relapse following nephrectomy.

Real-world, retrospective data showed that morphologic renal cell carcinoma types and tumor-stages helps to inform recurrence and prognosis.

Pembrolizumab with lenvatinib continued to demonstrate antitumor activity and led to longer survival rates vs historical controls in patients with advanced non–clear cell renal cell carcinoma.

First-line lenvatinib and pembrolizumab showed similar overall survival rates and improved progression-free survival and response rates vs global standard-of-care immunotherapies among patients with advanced renal cell carcinoma.

Patients with advanced/metastatic clear cell renal cell carcinoma who received belzutifan took longer to experience worsening symptoms and reported higher quality-of-life scores on questionnaires.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the case of an older patient with metastatic renal cell carcinoma who had recurrent disease after receiving axitinib and pembrolizumb, then single-agent cabozantinib. This is the first of 2 articles based on this event.